Kintara Therapeutics (KTRA) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kintara Therapeutics has corrected its previous announcement regarding the issuance of Contingent Value Rights (CVRs) related to its planned merger with TuHURA Biosciences. The CVRs will now be issued to stockholders immediately before a planned reverse stock split, aligning with the upcoming merger scheduled for October 18, 2024.
For further insights into KTRA stock, check out TipRanks’ Stock Analysis page.